Company Overview and News

5
October 2018 - Watch List / 1 Sale

2018-10-09 seekingalpha
It's Monday Morning and here in Canada it's thanksgiving. So happy Thanksgiving! Life is pretty good and I have a lot to be thankful for.
DRG.UN LRCDF IPL BNS MFC 0945 BNS MFC LB IPPLF

 
Dream Global REIT: German Real Estate Yielding Close To 6% - Assessing The Risks

2018-10-08 seekingalpha
Dream Global, however, has little to fear from interest rates in North America. Rates in the Eurozone are unlikely to rise meaningfully.
DRG.UN DUNDF

 
Dream Global REIT September 2018 Monthly Distribution

2018-09-18 globenewswire
TORONTO, Sept. 18, 2018 (GLOBE NEWSWIRE) -- DREAM GLOBAL REIT (TSX: DRG.UN, FRA: DRG) today announced its September 2018 monthly distribution in the amount of 6.667 cents per unit (80 cents annualized). The September distribution will be payable on October 15, 2018 to unitholders of record as at September 28, 2018.
DRG.UN

1
Dream Global REIT Appoints New CFO

2018-09-14 globenewswire
TORONTO, Sept. 14, 2018 (GLOBE NEWSWIRE) -- DREAM GLOBAL REIT (TSX: DRG.UN, FRA: DRG) is pleased to announce the appointment of Mr. Rajeev Viswanathan as the Trust’s Chief Financial Officer effective September 14, 2018.
DRG.UN BAMGF BAMKF BAM D.UN

 
Dream Office REIT Appoints New CFO

2018-09-14 globenewswire
TORONTO, Sept. 14, 2018 (GLOBE NEWSWIRE) -- DREAM OFFICE REIT (D.UN-TSX) is pleased to announce the appointment of Mr. Jay Jiang as the Trust's Chief Financial Officer effective September 14, 2018.
DRG.UN D.UN

 
Dream Global REIT: Positive Market Trend Should Continue

2018-09-11 seekingalpha
Dream Global REIT has a portfolio of office properties in Germany, the Netherlands, Austria, and Belgium.
DRG.UN DUNDF

 
Dream Global REIT: The Dream Run Continues, More To Come?

2018-08-24 seekingalpha
Dream Global REIT (OTC:DUNDF), which trades primarily on the Toronto Stock Exchange under the ticker DRG.UN.TO but has its assets in Western Europe, has delivered stellar total returns to shareholders over the past 18 months.
DRG.UN DUNDF DPSTF DPSGY

 
Dream Global REIT August 2018 Monthly Distribution

2018-08-21 globenewswire
TORONTO, Aug. 21, 2018 (GLOBE NEWSWIRE) -- DREAM GLOBAL REIT (TSX: DRG.UN, FRA: DRG) today announced its August 2018 monthly distribution in the amount of 6.667 cents per unit (80 cents annualized). The August distribution will be payable on September 17, 2018 to unitholders of record as at August 31, 2018.
DRG.UN

 
Dream Global REIT Real Estate Investment Trust's (DUNDF) CEO Jane Gavan on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Dream Industrial Real Estate Investment Trust (OTC:DUNDF) Q2 2018 Results Earnings Conference Call August 8, 2018 11:00 PM ET
DRG.UN DUNDF DREUF DPSTF DPSGY

 
Dream Global REIT July 2018 Monthly Distribution

2018-07-19 globenewswire
TORONTO, July 19, 2018 (GLOBE NEWSWIRE) -- DREAM GLOBAL REIT (TSX:DRG.UN) (FRA:DRG) today announced its July 2018 monthly distribution in the amount of 6.667 cents per unit (80 cents annualized). The July distribution will be payable on August 15, 2018 to unitholders of record as at July 31, 2018.
DRG.UN

 
Dream Global REIT Q2 2018 Financial Results

2018-07-12 globenewswire
TORONTO, July 12, 2018 (GLOBE NEWSWIRE) -- DREAM GLOBAL REIT (TSX:DRG.UN) (FRA:DRG) will be releasing its financial results for the quarter ended June 30, 2018, on Tuesday, August 7, 2018.
DRG.UN

 
Dream Global REIT Completes $201 Million Equity Offering

2018-06-26 globenewswire
TORONTO, June 26, 2018 (GLOBE NEWSWIRE) -- DREAM GLOBAL REIT (TSX:DRG.UN) (FRA:DRG) (“Dream Global REIT” or the “Trust”) announced today the closing of its previously announced equity offering of units of the Trust ("Units”) at a price of $14.60 per Unit (the “Offering”). The syndicate of underwriters, led by TD Securities Inc., elected to exercise its over-allotment option in full, resulting in a total of 13,800,000 Units being issued today for total gross proceeds of $201,480,000.
DRG.UN

5
Minto Apartment REIT is said to raise $200 million in Canada IPO

2018-06-22 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
DRG.UN TNTTF TD TD

 
Dream Global REIT June 2018 Monthly Distribution

2018-06-19 globenewswire
TORONTO, June 19, 2018 (GLOBE NEWSWIRE) -- DREAM GLOBAL REIT (TSX:DRG.UN) (FRA:DRG) today announced its June 2018 monthly distribution in the amount of 6.667 cents per unit (80 cents annualized). The June distribution will be payable on July 16, 2018 to unitholders of record as at June 29, 2018.
DRG.UN

 
REITs are defying the odds

2018-06-09 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
DRG.UN NVU.UN DIR.UN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...